Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clare L Scott

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
Breast Cancer Research : BCR|March 2, 2006
Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resourceGraham J Mann, Heather Thorne, Rosemary L Balleine, et al.
Therapeutic Advances in Medical Oncology|November 29, 2023
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft modelsGwo Yaw Ho, Cassandra J Vandenberg, Ratana Lim, et al.
JCO Precision Oncology|February 1, 2022
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE StudyOlga Kondrashova, Gwo-Yaw Ho, George Au-Yeung, et al.
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
Nature Communications|May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancerElaine Sanij, Katherine M Hannan, Jiachen Xuan, et al.
EMBO Molecular Medicine|March 12, 2021
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancerMichal M Hoppe, Patrick Jaynes, Joanna D Wardyn, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trialJonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 3, 2020
RAF1 rearrangements are common in pancreatic acinar cell carcinomasOwen W J Prall, Violeta Nastevski, Huiling Xu, et al.
British Journal of Cancer|July 8, 2026
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trialKatrin M Sjoquist, Alexander Dobrovic, Kristy P Robledo, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Breast Cancer Research : BCR|March 2, 2006
Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resourceGraham J Mann, Heather Thorne, Rosemary L Balleine, et al.
Therapeutic Advances in Medical Oncology|November 29, 2023
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft modelsGwo Yaw Ho, Cassandra J Vandenberg, Ratana Lim, et al.
JCO Precision Oncology|February 1, 2022
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE StudyOlga Kondrashova, Gwo-Yaw Ho, George Au-Yeung, et al.
Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.
Nature Communications|May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancerElaine Sanij, Katherine M Hannan, Jiachen Xuan, et al.
EMBO Molecular Medicine|March 12, 2021
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancerMichal M Hoppe, Patrick Jaynes, Joanna D Wardyn, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2025
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trialJonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 3, 2020
RAF1 rearrangements are common in pancreatic acinar cell carcinomasOwen W J Prall, Violeta Nastevski, Huiling Xu, et al.
British Journal of Cancer|July 8, 2026
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trialKatrin M Sjoquist, Alexander Dobrovic, Kristy P Robledo, et al.
Pageof 11